Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
IMMUNIC, INC. (VTL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/06/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 02/26/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Investor presentation, Quarterly results |
| 08/03/2020 |
8-K
| Quarterly results |
| 05/08/2020 |
8-K
| Quarterly results |
| 03/16/2020 |
8-K
| Quarterly results |
| 11/07/2019 |
8-K
| Quarterly results|
Docs:
|
"Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity NEW YORK, November 7, 2019 – Immunic, Inc. , a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ended September 30, 2019 and highlighted recent activity. “The third quarter was marked by several key clinical milestones. Chief among them was the early completion of enrollment for our phase 2 EMPhASIS trial for IMU-838 in relapsing-remitting multiple sclerosis, nine months ahead of initial expectation,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. “This achievement demonstrates our ability to execute on the ..." |
|
| 08/08/2019 |
8-K
| Quarterly results|
Docs:
|
"Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity SAN DIEGO, August 8, 2019 – Immunic, Inc. , a clinical-stage biopharmaceutical company focused on developing potentially best-in-class oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter ended June 30, 2019 and highlights recent activity. “The April closing of our transaction with Vital Therapies, listing on The Nasdaq Capital Market and capital infusion of $30 million from a key investor syndicate, have strengthened the company, increased our visibility and allowed the team to meaningfully progress and soon expand our product pipeline,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. “..." |
|
| 03/04/2019 |
8-K
| Quarterly results |
| 08/07/2018 |
8-K
| Quarterly results |
| 05/08/2018 |
8-K
| Quarterly results |
| 03/13/2018 |
8-K
| Quarterly results|
Docs:
|
"Vital Therapies Announces fourth quarter and full year 2017 Financial Results - VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12 - On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO, March 13, 2018 -- Vital Therapies, Inc. , a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and fiscal year ended December 31, 2017. “As VTL-308 nears completion, I am proud of the job our team has done in designing and running this pivotal trial,” said Russell J. Cox, the Company’s Chief Executive Officer. “Not only do baseline characteristics of subjects continue to track closely to the reference population, but also, blended event rates we..." |
|
| 10/25/2017 |
8-K
| Quarterly results |
| 08/03/2017 |
8-K
| Quarterly results|
Docs:
|
"Vital Therapies Announces second quarter 2017 Financial Results - 95 of Targeted 150 Subjects Enrolled in VTL-308 as of August 2nd SAN DIEGO, August 3, 2017 -- Vital Therapies, Inc. , a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2017. Key Recent Developments • Since the Company’s last quarterly update reported on May 9, 2017, enrollment has continued at a rate of about 9 subjects per month at sites in the United States and Europe in VTL-308, the Company’s phase 3 randomized, controlled, open-label trial, designed to evaluate the ELAD System in subjects with severe alcoholic hepatitis . As of August 2nd , 95 subjects were enrolled in the trial with 49 sit..." |
|
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 03/07/2017 |
8-K
| Form 8-K - Current report |
| 11/03/2016 |
8-K
| Form 8-K - Current report |
| 08/02/2016 |
8-K
| Quarterly results|
Docs:
|
"Vital Therapies Announces second quarter Financial Results SAN DIEGO, August 2, 2016 -- Vital Therapies, Inc. , a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2016. Key Recent Developments • Eight subjects have been enrolled at sites in the United States and Europe in VTL-308, the Company’s phase 3 randomized, controlled, open-label trial, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis . There are now 23 sites open for enrollment in VTL-308. • Raised net proceeds of $8.8 million through June 30, 2016 under an existing “at-the-market,” or ATM, sales agreement since initiating the program in March 2016. The Company has..." |
|
|
|